Pterostilbene vs Resveratrol: Which Has Better Senolytic Evidence?

Evidence correction: Pterostilbene has not been shown to clear senescent cells or extend human lifespan.

Expert Summary

Resveratrol excited the aging research world with its potent SIRT1 activation and lifespan extension in simple organisms. However, its oral bioavailability of <1% in humans limits plasma levels far below concentrations needed for observed biological effects. Pterostilbene (a dimethylated resveratrol analog from blueberries) achieves 80% bioavailability while maintaining equivalent or superior SIRT1 activation.

Key Facts

Frequently Asked Questions

Should I take pterostilbene instead of resveratrol?

For oral supplementation purposes, pterostilbene's dramatically superior bioavailability makes it the more rational choice. If you want the benefits that resveratrol research suggests, pterostilbene actually delivers relevant plasma concentrations.

Can pterostilbene extend human lifespan?

No direct human lifespan evidence exists. It activates SIRT1 (a validated longevity pathway) and reduces inflammatory/aging markers. Whether this translates to lifespan extension in humans cannot be confirmed with current evidence.

Scientific References

Pterostilbene is not a clinically proven senolytic

Pterostilbene is a plant-derived stilbene related to resveratrol. Cell and animal experiments have explored effects on oxidative signaling, inflammation, and cell survival, but these findings do not establish selective senescent-cell clearance in people. There is no human trial showing that pterostilbene supplements clear senescent cells, prevent age-related disease, or extend lifespan.

One randomized, double-blind trial enrolled 80 adults with elevated cholesterol and compared 50 mg twice daily, 125 mg twice daily, a lower-dose combination with grape extract, and placebo for 6–8 weeks. It was a short metabolic study, not a senolytic trial. Pterostilbene monotherapy was associated with an increase in LDL cholesterol in the trial analysis, so “more bioavailable resveratrol” should not be assumed to mean safer or more effective.

Practical and safety considerations

There is no established dose for senolytic use. A study dose is not a recommendation, particularly when the study was not testing aging or cell clearance. If you are considering a supplement, review the reason with a clinician and check the complete ingredient label. People using cholesterol-lowering therapy, anticoagulants, antiplatelet drugs, or medicines metabolized by the liver should ask about potential interactions and lipid monitoring.

Do not replace prescribed cardiovascular treatment with pterostilbene. If a lipid panel changes after starting a supplement, discuss it with a clinician rather than assuming the result is incidental.

FAQ

Does pterostilbene remove senescent cells in humans? That has not been demonstrated.

Is it better than resveratrol? Greater exposure in some pharmacokinetic comparisons does not prove better clinical outcomes.

Read the resveratrol senolytic evidence review and senolytics clinical-trials guide.

Research: Randomized placebo-controlled pterostilbene trial; safety analysis of the same 80-person trial.

Get the free Longevity Supplement Starter Guide

Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.